TOP TEN perturbations for 1553443_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553443_at
Selected probe(set): 1553443_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553443_at (1553443_at) across 6537 perturbations tested by GENEVESTIGATOR:

Parkinson's disease study 8 / normal external globus pallidus tissue

Relative Expression (log2-ratio):-0.6689844
Number of Samples:4 / 2
Experimental Parkinson's disease study 8
External globus pallidus tissue from patients with Parkinson's disease.
Control normal external globus pallidus tissue
Normal external globus pallidus tissue.

HCC study 27 (young; validation) / HCC study 27 (elder; validation)

Relative Expression (log2-ratio):-0.6637726
Number of Samples:21 / 10
Experimental HCC study 27 (young; validation)
Primary tumor tissue samples obtained from the liver of young patients (≤ 40 years old) with hepatocellular carcinoma assigned to a validation cohort.
Control HCC study 27 (elder; validation)
Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a validation cohort.

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-0.6148896
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

HCC study 27 (elder; validation) / HCC study 27 (elder; training)

Relative Expression (log2-ratio):0.59216404
Number of Samples:10 / 32
Experimental HCC study 27 (elder; validation)
Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a validation cohort.
Control HCC study 27 (elder; training)
Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a training cohort.

asthma study 38 (large airway epithelium cell) / normal bronchial (primary, main stem) epithelium cell sample

Relative Expression (log2-ratio):-0.5832281
Number of Samples:11 / 20
Experimental asthma study 38 (large airway epithelium cell)
Bronchial (primary, main stem) epithelium cell samples collected by fibre-optic bronchoscopy from patients who suffered from severe asthma. The severe asthma patients were on step 4 or 5 of GINA guidelines therapy, had poorly controlled disease with an Asthma Control Questionnaire (ACQ) score of ≥1.5 and fulfilled the International ERS/ATS criteria for severe asthma. All were current non-smokers. They were on a mean daily inhaled steroid dose (beclometasone equivalents) of 2729 micrograms (range 2000-4400 μg). All were on daily therapy with inhaled long acting beta agonists. All had also received at some time oral therapy with montelukast 10mg nocte, with 10 currently on this treatment. All the severe asthmatics had a history of at least 2 exacerbations in the last year (range 2-12) and several subjects had a history of hospital admission for acute severe asthma in the last year.
Control normal bronchial (primary, main stem) epithelium cell sample
Normal bronchial (primary, main stem) epithelium cell samples collected by fibre-optic bronchoscopy from healthy non-asthmatic volunteers. Central brushes were taken under direct vision from the right bronchus intermedius. Subjects' characteristics: no history of respiratory disease, no current symptoms and no drop in forced expiratory volume in one second (FEV1) with inhaled methacholine at 16mg/mL, current non-smokers.

BMP-2 study 5 (dorsomorphin) / BMP-2 study 5 (BMP-2)

Relative Expression (log2-ratio):-0.5668316
Number of Samples:3 / 3
Experimental BMP-2 study 5 (dorsomorphin)
SK-OV-3 cells treated with dorsomorphin (5uM) for 24 hours. ATC code:---
Control BMP-2 study 5 (BMP-2)
SK-OV-3 cells treated with recombinant bone morphogenic protein 2 (rBMP2; 100 ng/ml) for 24 hours. ATC code:---

peptidoglycan study 1 / mock treated neonatal neutrophils

Relative Expression (log2-ratio):0.55891323
Number of Samples:3 / 3
Experimental peptidoglycan study 1
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery treated with peptidoglycan isolated from S. aureus (10 ug/ml) for 4 hours.
Control mock treated neonatal neutrophils
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery mock treated for 4 hours.

diclofenac study 7 (24h) / vehicle (PBS) treated HepG2 cell sample

Relative Expression (log2-ratio):0.5044751
Number of Samples:3 / 3
Experimental diclofenac study 7 (24h)
HepG2 cells exposed to 100μM diclofenac in PBS solvent for 24 hours. ATC code:, ,
Control vehicle (PBS) treated HepG2 cell sample
HepG2 cells exposed to 0.5% PBS solvent for 24 hours.

TNF-ɑ study 8 (0.1ng/ml) / vehicle (HBSS) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):-0.50043106
Number of Samples:3 / 3
Experimental TNF-ɑ study 8 (0.1ng/ml)
Bronchial epithelial cells (NHBE) treated with 0.1 ng/ml TNFalpha for 4 hours. NHBE cells were derived from a male donor.
Control vehicle (HBSS) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (HBSS) for 4 hours. NHBE cells were derived from a male donor.

Olea pollen extract study 1 (allergic; pollen season) / Olea pollen extract study 1 (non-allergic; pollen season)

Relative Expression (log2-ratio):0.49505806
Number of Samples:3 / 2
Experimental Olea pollen extract study 1 (allergic; pollen season)
Peripheral blood mononuclear cells (PBMC) obtained during pollen season (April-June) from pollen-allergic patients were cultured for 24 hours in the presence of whole olive pollen extract (25µg/ml). The patients fulfilled the following criteria: seasonal rhinitis and/or asthma, a positive skin prick test for O. europaea pollen extract, and no previous immunotherapy. Each sample represents equimolar amounts of RNA from two subjects, samples were pooled prior labeling and hybridization. (Warning: Experiment with gender bias).
Control Olea pollen extract study 1 (non-allergic; pollen season)
Peripheral blood mononuclear cells (PBMC) obtained during pollen season (April-June) from patients with no history of respiratory allergies were cultured for 24 hours in the presence of whole olive pollen extract (25µg/ml). All subjects underwent skin prick test for olive pollen allergy with whole O. europaea extract and a battery of common allergens. Each sample represents equimolar amounts of RNA from two subjects, samples were pooled prior labeling and hybridization. (Warning: Experiment with gender bias).